Journal of Neurology

, Volume 255, Supplement 6, pp 15–21 | Cite as

Immunomodulatory treatment strategies in multiple sclerosis

  • Bernd C. Kieseier
  • Heinz Wiendl
  • Verena I. Leussink
  • Olaf Stüve


Multiple sclerosis (MS) represents the prototypic inflammatory autoimmune disorder of the central nervous system and the most common cause of neurological disability in young adults. The mainstays in the immunomodulatory therapy of MS are currently interferon beta and glatiramer acetate, both of which have proven to be clinically and paraclinically effective. Current clinical evidence indicates that treatment should be initiated as early as possible. In this review we summarize available data from clinical studies on clinical efficacy of immunomodulatory drugs for treating patients with multiple sclerosis.

Key words

multiple sclerosis immunomodulation interferon beta glatiramer acetat 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH, Comi G, Ader HJ, Losseff N, Valk J (1997) Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120:2059–2069PubMedCrossRefGoogle Scholar
  2. 2.
    Beck RW, Chandler DL, Cole SR, Simon JH, Jacobs LD, Kinkel RP, Selhorst JB, Rose JW, Cooper JA, Rice G, Murray TJ, Sandrock AW (2002) Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 51:481–490PubMedCrossRefGoogle Scholar
  3. 3.
    Brex PA, Ciccarelli O, O’Riordan JI, Sailer M, Thompson AJ, Miller DH (2002) A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 346:158–164PubMedCrossRefGoogle Scholar
  4. 4.
    Brex PA, O’Riordan JI, Miszkiel KA, Moseley IF, Thompson AJ, Plant GT, Miller DH (1999) Multisequence MRI in clinically isolated syndromes and the early development of MS. Neurology 53:1184–1190PubMedGoogle Scholar
  5. 5.
    Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, Sandrock AW, Rudick RA, Simon JH, Simonian NA, Tsao EC, Whitaker JN (2002) Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 59:679–687PubMedGoogle Scholar
  6. 6.
    Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, Hartung H, Seeldrayers P, Sorensen PS, Rovaris M, Martinelli V, Hommes OR (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357:1576–1582PubMedCrossRefGoogle Scholar
  7. 7.
    Comi G, Filippi M, Wolinsky JS (2001) European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 49:290–297PubMedCrossRefGoogle Scholar
  8. 8.
    Compston A, Coles A (2002) Multiple sclerosis. Lancet 359:1221–1231PubMedCrossRefGoogle Scholar
  9. 9.
    Corboy JR, Goodin DS, Frohman EM (2003) Disease-modifying Therapies for Multiple Sclerosis. Curr Treat Options Neurol 5:35–54PubMedCrossRefGoogle Scholar
  10. 10.
    Coyle PK, Hartung HP (2002) Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response. Mult Scler 8:2–9PubMedGoogle Scholar
  11. 11.
    Dalton CM, Brex PA, Miszkiel KA, Hickman SJ, MacManus DG, Plant GT, Thompson AJ, Miller DH (2002) Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 52:47–53PubMedCrossRefGoogle Scholar
  12. 12.
    European Study Group on interferon beta-1b in secondary progressive MS (1998) Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352:1491–1497Google Scholar
  13. 13.
    Farina C, Weber MS, Meinl E, Wekerle H, Hohlfeld R (2005) Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol 4:567–575PubMedCrossRefGoogle Scholar
  14. 14.
    Fazekas F, Barkhof F, Filippi M, Grossman RI, Li DK, McDonald WI, McFarland HF, Paty DW, Simon JH, Wolinsky JS, Miller DH (1999) The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology 53:448–456PubMedGoogle Scholar
  15. 15.
    Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, Thompson AJ, Miller DH (2008) Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 131:808–817PubMedCrossRefGoogle Scholar
  16. 16.
    Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343:898–904PubMedCrossRefGoogle Scholar
  17. 17.
    Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Slazar AM, et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285–294PubMedCrossRefGoogle Scholar
  18. 18.
    Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 45:1268–1276PubMedGoogle Scholar
  19. 19.
    Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS (1998) Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 50:701–708PubMedGoogle Scholar
  20. 20.
    Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Bauer L, Dahms S, Lanius V, Pohl C, Sandbrink R; BENEFIT Study Group (2007) Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370:389–397PubMedCrossRefGoogle Scholar
  21. 21.
    Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Bauer L, Jakobs P, Pohl C, Sandbrink R (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67:1242–1249PubMedCrossRefGoogle Scholar
  22. 22.
    Kappos L, Weinshenker B, Pozzilli C, Thompson AJ, Dahlke F, Beckmann K, Polman C, McFarland H; European (EU-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board; North American (NA-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board (2004) Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 63:1779–1787PubMedGoogle Scholar
  23. 23.
    Kieseier BC, Hemmer B, Hartung HP (2005) Multiple sclerosis – novel insights and new therapeutic strategies. Curr Opin Neurol 18:211–220PubMedCrossRefGoogle Scholar
  24. 24.
    Kieseier BC, Seifert T, Giovannoni G, Hartung HP (1999) Matrix metalloproteinases in inflammatory demyelination: targets for treatment. Neurology 53:20–25PubMedGoogle Scholar
  25. 25.
    Kieseier BC, Wiendl H (2007) Oral disease-modifying treatments for multiple sclerosis: the story so far. CNS Drugs 21:483–502PubMedCrossRefGoogle Scholar
  26. 26.
    Kinkel RP, Kollman C, O’Connor P, Murray TJ, Simon J, Arnold D, Bakshi R, Weinstock-Gutman B, Brod S, Cooper J, Duquette P, Eggenberger E, Felton W, Fox R, Freedman M, Galetta S, Goodman A, Guarnaccia J, Hashimoto S, Horowitz S, Javerbaum J, Kasper L, Kaufman M, Kerson L, Mass M, Rammohan K, Reiss M, Rolak L, Rose J, Scott T, Selhorst J, Shin R, Smith C, Stuart W, Thurston S, Wall M; CHAMPIONS Study Group (2006) IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 66:678–684PubMedCrossRefGoogle Scholar
  27. 27.
    Li DK, Paty DW (1999) Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. Ann Neurol 46:197–206PubMedCrossRefGoogle Scholar
  28. 28.
    McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127PubMedCrossRefGoogle Scholar
  29. 29.
    McFarland HF, Barkhof F, Antel J, Miller DH (2002) The role of MRI as a surrogate outcome measure in multiple sclerosis. Mult Scler 8:40–51PubMedGoogle Scholar
  30. 30.
    Miller A, Spada V, Beerkircher D, Kreitman RR (2008) Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler 14:494–499PubMedCrossRefGoogle Scholar
  31. 31.
    Miller DH, Leary SM (2007) Primary-progressive multiple sclerosis. Lancet Neurol 6:903–912PubMedCrossRefGoogle Scholar
  32. 32.
    Optic, Neuritis, Study, Group (1997) The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Neurology 49:1404–1413Google Scholar
  33. 33.
    Panitch H, Miller A, Paty D, Weinshenker B; North American Study Group on Interferon beta-1b in Secondary Progressive MS (2004) Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 63:1788–1795PubMedGoogle Scholar
  34. 34.
    Paty DW, Li DK, UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, doubleblind, placebo-controlled trial. Neurology 43:662–667PubMedGoogle Scholar
  35. 35.
    Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O’Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58:840–846PubMedCrossRefGoogle Scholar
  36. 36.
    PRISMS Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498–1504Google Scholar
  37. 37.
    PRISMS Study Group (2001) PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 56:1628–1636Google Scholar
  38. 38.
    Rodriguez M, Siva A, Cross SA, O’Brien PC, Kurland LT (1995) Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology 45:244–250PubMedGoogle Scholar
  39. 39.
    Rudick RA, Goodkin DE, Jacobs LD, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Fischer JS, Granger CV, Simon JH, Alam JJ, Simonian NA, Campion MK, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Whitham RH, et al. (1997) Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 49:358–363PubMedGoogle Scholar
  40. 40.
    Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Alam JJ, Fischer JS, Goodkin DE, Granger CV, Lajaunie M, Martens-Davidson AL, Meyer M, Sheeder J, Choi K, Scherzinger AL, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Whitham RH, et al. (1998) Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 43:79–87PubMedCrossRefGoogle Scholar
  41. 41.
    SPECTRIMS Study Group (2001) Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. Neurology 56:1496–1504Google Scholar
  42. 42.
    Stüve O, Bennett JL, Hemmer B, Wiendl H, Racke MK, Bar-Or A, Hu W, Zivadinov R, Weber MS, Zamvil SS, Pacheco MF, Menge T, Hartung HP, Kieseier BC, Frohman EM (2008) Pharmacological treatment of early multiple sclerosis. Drugs 68:73–83PubMedCrossRefGoogle Scholar
  43. 43.
    The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655–661Google Scholar
  44. 44.
    The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45:1277–1285Google Scholar
  45. 45.
    The Once Weekly Interferon for MS Study Group (1999) Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. Neurology 11:679–686Google Scholar
  46. 46.
    Tintore M, Rovira A, Martinez MJ, Rio J, Diaz-Villoslada P, Brieva L, Borras C, Grive E, Capellades J, Montalban X (2000) Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol 21:702–706PubMedGoogle Scholar
  47. 47.
    Tintoré M, Rovira A, Río J, Tur C, Pelayo R, Nos C, Téllez N, Perkal H, Comabella M, Sastre-Garriga J, Montalban X (2008) Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 70:1079–1083PubMedCrossRefGoogle Scholar
  48. 48.
    Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC (1989) The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 112:133–146PubMedCrossRefGoogle Scholar
  49. 49.
    Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC (1989) The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 112:1419–1428PubMedCrossRefGoogle Scholar
  50. 50.
    Wiendl H, Hohlfeld R (2002) Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 16:183–200PubMedCrossRefGoogle Scholar
  51. 51.
    Wolinsky JS, Comi G, Filippi M, Ladkani D, Kadosh S, Shifroni G (2002) Copaxone’s effect on MRI-monitored disease in relapsing MS is reproducible and sustained. Neurology 59:1284–1286PubMedGoogle Scholar
  52. 52.
    Wolinsky JS, Narayana PA, O’Connor P, Coyle PK, Ford C, Johnson K, Miller A, Pardo L, Kadosh S, Ladkani D; PROMiSe Trial Study Group (2007) Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 61:14–24PubMedCrossRefGoogle Scholar
  53. 53.
    Yong VW (2002) Differential mechanisms of action of interferon-beta and glatiramer aetate in MS. Neurology 59:802–808PubMedGoogle Scholar
  54. 54.
    Yong VW, Chabot S, Stuve O, Williams G (1998) Interferon beta in the treatmentof multiple sclerosis: mechanisms of action. Neurology 51:682–689PubMedGoogle Scholar
  55. 55.
    Ziemssen T, Neuhaus O, Hohlfeld R (2001) Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug Saf 24:979–990PubMedCrossRefGoogle Scholar

Copyright information

© Steinkopff-Verlag 2008

Authors and Affiliations

  • Bernd C. Kieseier
    • 1
  • Heinz Wiendl
    • 2
  • Verena I. Leussink
    • 1
  • Olaf Stüve
    • 3
    • 4
  1. 1.Dept. of NeurologyHeinrich-Heine UniversityDüsseldorfGermany
  2. 2.Dept. of NeurologyJulius-Maximilians UniversityWürzburgGermany
  3. 3.Neurology SectionVA North Texas Health Care System Medical ServiceDallasUSA
  4. 4.Dept. of Neurology and Dept. of ImmunologyUniversity of Texas Southwestern Medical Center at DallasDallasUSA

Personalised recommendations